I recently posted an ‘Onc Live’ video series about Neuroendocrine Tumour (NET) treatments and the final episode talked about combination treatments i.e. where more than one treatment is administered simultaneously.  An interesting and exciting area to watch for the treatment of NET patients.

Thought you’d be interested in a potential new treatment being developed in Australia.  The use of PRRT and chemo (in particular CAPTEM) or ‘PRCRT’. The attached video is a presentation by Dr Michael Hofman who I see regularly on twitter posting some very interesting stuff. He’s a great advocate for NET patients. The video will explain in some detail how the treatment is thought to work together. Additionally, it also provides excellent PRRT information. Dr Hofman has some really interesting things to say.  20 minutes – definitely recommended watching!  CLICK HERE

‘CONTROLNETS’ involving PRRT and CAPTEM. The details of the trial can be read here: CLICK HERE.

The first results of this trial were presented at ASCO 2020 and they concluded “This initial planned analysis demonstrates similarly high 15-month PFS for CAPTEM/PRRT relative to PRRT alone. OTRR is numerically higher but at the cost of greater toxicity. Longer follow up is required to determine if the activity of PRRT/CAPTEM is sufficient to warrant Phase III evaluation” – click here to read the abstract.